Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Rhabdomyolysis in Acute COVID-19 Infection: A Descriptive Outcomes Analysis
Infectious Disease
P9 - Poster Session 9 (8:00 AM-9:00 AM)
13-010
To evaluate the impact of rhabdomyolysis on clinical outcomes of acute SARS CoV-2 infection.
Rhabdomyolysis has been reported as a complication of severe SARS CoV-2 infection.
We conducted a retrospective analysis of extracted EMR data from the EPIC Electronic Medical Record System. We identified 72,772 patients with acute COVID-19 infection with concomitant rhabdomyolysis (CWR) and 13,954,933 patients with acute COVID-19 infection and no rhabdomyolysis (CNR). A sample of non-COVID patients was used to compare the difference of rhabdomyolysis prevalence.
Rhabdomyolysis was more prevalent with concomitant COVID-19 than in the general population, 0.54% vs 0.16%, (P<0.05). CWR patients had significantly higher mortality rates (CWR/CNR: 13.9% vs 1.8%; p<0.05),higher rates of hospice discharges, (CWR/CNR: 4.9% vs 0.7%; p<0.05),higher SNF placement rates (CWR/CNR: 31.7% vs 3.2%; p<0.05), a higher mechanical ventilation requirements (CWR/CNR: 19.1% vs 1.7%; p<0.05), a greater BMI (CWR/CNR: 53.9% vs 43.2%; p<0.05), a longer hospital length of stay (CWR/CNR: 8.1±0.13 days vs 6.2±0.02 days; p<0.05), older age (CWR/CNR: 61±0.15 years vs 46±0.01 years; p<0.05), and a higher disability rate (CWR/CNR: 15.2% vs 2.7%; p<0.05). A significantly higher proportion of patients in CWR were male compared to CNR (CWR M/F: 64.3%/35.7% vs P2 M/F: 43.2%/56.8%; p<0.05).
Concomitant rhabdomyolysis in acute COVID-19 significantly increases mortality and morbidity. Rhabdomyolysis in this cohort is associated with older age, greater BMI, and an increase in disability rate.
Authors/Disclosures
Roopa Sharma, MD
PRESENTER 		Dr. Sharma has nothing to disclose.
Kazim Jaffry Mr. Jaffry has nothing to disclose.
Justin Matos No disclosure on file
Scott Karpenos No disclosure on file
James Lin, MS Mr. Lin has nothing to disclose.
Narjis Jaffry No disclosure on file
Suhayb Islam (Rutgers University) Mr. Islam has nothing to disclose.
Kranthi K. Mandava Mr. Mandava has nothing to disclose.
Daniel L. Menkes, MD, FÂ鶹´«Ã½Ó³»­ (Neuroscience Center) An immediate family member of Dr. Menkes has received personal compensation for serving as an employee of NIH. An immediate family member of Dr. Menkes has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for CMTE. An immediate family member of Dr. Menkes has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NIH. Dr. Menkes has received personal compensation in the range of $100,000-$499,999 for serving as an Expert Witness for Self Employed. An immediate family member of Dr. Menkes has received research support from Helmsley Foundation . An immediate family member of Dr. Menkes has received intellectual property interests from a discovery or technology relating to health care.
Nizar Souayah, MD, FÂ鶹´«Ã½Ó³»­ (NJMS) Dr. Souayah has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Takeda. Dr. Souayah has received publishing royalties from a publication relating to health care.